Analytical Data
-
基因名
CHI3L1
-
简介
The CHI3L1 protein is a binding lectin that lacks chitinase activity. CHI3L1 contributes to tissue remodeling, cellular adaptation to environmental changes, and T helper type 2 inflammatory responses. CHI3L1 also controls hyperoxia-induced injury, inflammation, and epithelial cell apoptosis. CHI3L1 Protein, Human (HEK293, His) is the recombinant human-derived CHI3L1 protein, expressed by HEK293 , with C-6*His labeled tag.
- Application
-
生物活性
Measured by the ability of the immobilized protein to support the adhesion of FaDu human squamous cell carcinoma cells. The ED50 for this effect is 0.6-3.0 μg/mL. Measured by the ability of the immobilized protein to support the adhesion of FaDu human squamous cell carcinoma cells. The ED50 for this effect is 2.603 μg/mL, corresponding to a specific activity is 384.1721 units/mg.
-
别名
rHuChitinase-3-like protein 1/CHI3L1, His; Chitinase-3-Like protein 1; 39 kDa Synovial Protein; Cartilage Glycoprotein 39; CGP-39; GP-39; hCGP-39; YKL-40; CHI3L1
-
种属
Human
-
表达系统
HEK293
-
标签
C-6*His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P36222
-
表达区间
Y22-T383
-
氨基酸序列
YKLVCYYTSWSQYREGDGSCFPDALDRFLCTHIIYSFANISNDHIDTWEWNDVTLYGMLNTLKNRNPNLKTLLSVGGWNFGSQRFSKIASNTQSRRTFIKSVPPFLRTHGFDGLDLAWLYPGRRDKQHFTTLIKEMKAEFIKEAQPGKKQLLLSAALSAGKVTIDSSYDIAKISQHLDFISIMTYDFHGAWRGTTGHHSPLFRGQEDASPDRFSNTDYAVGYMLRLGAPASKLVMGIPTFGRSFTLASSETGVGAPISGPGIPGRFTKEAGTLAYYEICDFLRGATVHRILGQQVPYATKGNQWVGYDDQESVKSKVQYLKDRQLAGAMVWALDLDDFQGSFCGQDLRFPLTNAIKDALAAT
-
蛋白长度
Full Length of Mature Protein
-
分子量
41-46 kDa band in SDS-PAGE under reducing conditions.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CHI3L1, also known as chitinase 3-like 1 or YKL-40, is a glycoprotein that has garnered significant attention in recent years due to its involvement in various pathological processes, particularly in inflammation and tissue remodeling. This protein is primarily expressed in macrophages, chondrocytes, and other cell types in response to pro-inflammatory stimuli. Elevated levels of CHI3L1 have been implicated in different diseases, including cancer, asthma, and autoimmune disorders, where it often serves as a biomarker for disease progression and severity. Research has suggested that CHI3L1 plays a crucial role in modulating inflammation and has potential implications for therapeutic intervention. The protein's ability to bind to chitin and its structural similarities to chitinases suggest that it may influence extracellular matrix dynamics and tissue repair processes. Consequently, recombinant CHI3L1 has emerged as a valuable tool for studying its biological functions, mechanisms of action, and potential clinical applications. Understanding the role of CHI3L1 in various diseases could lead to novel therapeutic strategies and improve diagnostic capabilities in inflammatory and degenerative conditions. The ongoing exploration of its multifaceted roles highlights the significance of CHI3L1 as a target for both research and clinical advancements.
